An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon
Zhu, J.; Deng, Y.-Q.; Wang, X.; Li, X.-F.; Zhang, N.-N.; Liu, Z.; Zhang, B.; Qin, C.; Xie, Z.
Show abstract
The pandemic COVID-19 has spread to all over the world and greatly threatens safety and health of people. COVID-19 is highly infectious and with high mortality rate. As no effective antiviral treatment is currently available, new drugs are urgently needed. We employed transcriptional analysis to uncover potential antiviral drugs from natural products or FDA approved drugs. We found liquiritin significantly inhibit replication of SARS-CoV-2 in Vero E6 cells with EC50 = 2.39 M. Mechanistically, we found liquiritin exerts anti-viral function by mimicking type I interferon. Upregulated genes induced by liquiritin are enriched in GO categories including type I interferon signaling pathway, negative regulation of viral genome replication and etc. In toxicity experiment, no death was observed when treated at dose of 300 mg/kg for a week in ICR mice. All the organ indexes but liver and serum biochemical indexes were normal after treatment. Liquiritin is abundant in licorice tablet (~0.2% by mass), a traditional Chinese medicine. Together, we recommend liquiritin as a competitive candidate for treating COVID-19. We also expect liquiritin to have a broad and potent antiviral function to other viral pathogens, like HBV, HIV and etc.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro 95%
- Evaluating the bioactivities of natural and synthetic fungal tropolone sesquiterpenoids in various cell lines 94%
- A small H2O-soluble ingredient of royal jelly lower cholesterol levels in liver cells by suppressing squalene epoxidase 93%
Similar papers in this journal
- Discovery of Z1362873773: A Novel Fascin Inhibitor from a Large Chemical Library for Colorectal Cancer 96%
- Mechanistic insights into the Japanese Encephalitis Virus RNA dependent RNA polymerase protein inhibition by bioflavonoids from Azadirachta indica 96%
- PeruNPDB: The Peruvian Natural Products Database for in silico drug screening 95%
Similar papers in this journal
- Support Vector Machine based prediction models for drug repurposing and designing novel drugs for colorectal cancer 94%
- Utilizing Heteroatom Types and Numbers from Extensive Ligand Libraries to Develop Novel hERG Blocker QSAR Models Using Machine Learning-based Classifiers 94%
- Chalcogen derivatives for the treatment of African trypanosomiasis: biological evaluation of thio and seleno- semicarbazones and their azole derivatives 93%
Similar papers in this journal
- Adverse PFAS effects on mouse oocyte in vitro maturation are associated with carbon-chain length and inclusion of a sulfonate group 88%
- THER: Integrative Web Tool for Tumor Hypoxia Exploration and Research 88%
- An in vivo drug screen reveals that cyclooxygenase 2-derived prostaglandin D2 promotes spinal cord neurogenesis. 86%
Similar papers in this journal
- Understanding the Mechanistic Contribution of Herbal Extracts in Compound Kushen Injection with Transcriptome Analysis 94%
- Osthole Suppresses Prostate Cancer Progression by Modulating PRLR and the JAK2/STAT3 Signaling Axis 93%
- Establishment of a prognosis prediction model based on pyroptosis-related signatures associated with the immune microenvironment and molecular heterogeneity in clear cell renal carcinoma 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.